Health Trials

Molecular Profiling for Risk Stratification in Appendiceal Cancer

ConditionsAppendiceal CancerAppendiceal Adenocarcinoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCity of Hope Medical Center

About this trial

This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.

Eligibility criteria

Qualifiers

Patients with histologically confirmed appendiceal adenocarcinoma or appendiceal cancer.

Availability of archived tumor tissue suitable for molecular profiling.

Availability of tissue for DNA methylation profiling, m6A epitranscriptomic profiling, or both.

Availability of relevant clinicopathologic data.

Disqualifiers

Insufficient tissue quantity or quality for molecular profiling.

Inadequate DNA or RNA quality for sequencing or molecular assay preparation.

Missing essential clinicopathologic information required for analysis.

Non-appendiceal primary tumor or metastatic tumor to the appendix from another primary site.

Trial design

Treatments tested in this trial

  • DNA Methylation Profiling
  • m6A Epitranscriptomic Profiling

Treatment groups

400 Participants
are divided into 2 treatment groups

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

City of Hope Medical CenterRecruiting91016, Durate, CaliforniaUnited StatesUnited States

Sponsors and collaborators

City of Hope Medical Center

Lead sponsor

Source ClinicalTrials.gov